600222 Stock Overview
Henan Taloph Pharmaceutical Stock Co.,Ltd engages in the research, development, and sale of Chinese medicines in China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Henan Taloph Pharmaceutical Stock Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.09 |
| 52 Week High | CN¥8.08 |
| 52 Week Low | CN¥3.75 |
| Beta | 0.62 |
| 1 Month Change | -4.14% |
| 3 Month Change | 8.07% |
| 1 Year Change | -15.59% |
| 3 Year Change | -15.59% |
| 5 Year Change | -1.74% |
| Change since IPO | -39.22% |
Recent News & Updates
Shareholder Returns
| 600222 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.6% | 2.7% | 1.2% |
| 1Y | -15.6% | -10.9% | -12.6% |
Return vs Industry: 600222 underperformed the CN Pharmaceuticals industry which returned -10.9% over the past year.
Return vs Market: 600222 underperformed the CN Market which returned -12.6% over the past year.
Price Volatility
| 600222 volatility | |
|---|---|
| 600222 Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 12.1% |
| 10% least volatile stocks in CN Market | 5.0% |
Stable Share Price: 600222 has not had significant price volatility in the past 3 months.
Volatility Over Time: 600222's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 2,353 | Jianchao Luo | www.taloph.com |
Henan Taloph Pharmaceutical Stock Co.,Ltd engages in the research, development, and sale of Chinese medicines in China. The company primarily offers its products in the forms of oral liquids, tablets, capsules, fluids, and others. Its principal products include Shuanghuanglian oral liquid series, Shuangjinlian mixture, Danshen oral liquid, Xiaoer Qingre Zhike oral liquid, pediatric compound Ji Neijin chewable tablets, and Huperzine A tablets.
Henan Taloph Pharmaceutical Stock Co.,Ltd Fundamentals Summary
| 600222 fundamental statistics | |
|---|---|
| Market cap | CN¥2.85b |
| Earnings (TTM) | CN¥61.13m |
| Revenue (TTM) | CN¥2.01b |
46.6x
P/E Ratio1.4x
P/S RatioIs 600222 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600222 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.01b |
| Cost of Revenue | CN¥1.46b |
| Gross Profit | CN¥544.57m |
| Other Expenses | CN¥483.43m |
| Earnings | CN¥61.13m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.11 |
| Gross Margin | 27.11% |
| Net Profit Margin | 3.04% |
| Debt/Equity Ratio | 49.9% |
How did 600222 perform over the long term?
See historical performance and comparison